URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Alan Katz

Concepts (149)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of pubs Most recent pub Pubs by all authors Concept score Why?
Radiosurgery
9
2006
73
2.060
Why?
Liver Neoplasms
7
2006
155
1.800
Why?
Neoplasm Metastasis
5
2006
229
1.070
Why?
Carcinoma, Hepatocellular
2
2011
71
0.990
Why?
Liver Transplantation
1
2011
244
0.670
Why?
Dose Fractionation
6
2006
57
0.510
Why?
Tumor Burden
4
2006
22
0.480
Why?
Neoplasms, Second Primary
3
1996
125
0.470
Why?
Lung Neoplasms
6
2000
435
0.460
Why?
Breast Neoplasms
4
2000
666
0.440
Why?
Retrospective Studies
11
1997
2302
0.440
Why?
Aged
22
1996
7392
0.430
Why?
Radiotherapy
2
2000
198
0.420
Why?
Aged, 80 and over
15
1997
2588
0.400
Why?
Vagina
1
2001
51
0.390
Why?
Endometrial Neoplasms
1
2001
38
0.390
Why?
Middle Aged
21
1996
10013
0.380
Why?
Brachytherapy
4
2000
109
0.380
Why?
Uterine Cervical Neoplasms
1
2001
125
0.370
Why?
Neoplasms, Radiation-Induced
1
2000
80
0.350
Why?
Carcinoma, Merkel Cell
4
1996
11
0.340
Why?
Skin Neoplasms
5
1996
230
0.340
Why?
Hodgkin Disease
1
2000
156
0.320
Why?
Female
23
1996
20222
0.310
Why?
Neoplasm Recurrence, Local
4
2000
295
0.300
Why?
Antineoplastic Combined Chemotherapy Protocols
4
1997
436
0.300
Why?
Adult
20
1996
11572
0.290
Why?
Humans
29
1996
37165
0.280
Why?
Stereotaxic Techniques
2
2006
33
0.280
Why?
Treatment Outcome
9
1997
2671
0.280
Why?
Brain Neoplasms
3
2006
282
0.280
Why?
Whole-Body Irradiation
2
2006
87
0.270
Why?
Male
19
1996
20139
0.230
Why?
Cholangiocarcinoma
1
2012
12
0.210
Why?
Waiting Lists
1
2011
12
0.210
Why?
Airway Obstruction
2
2000
39
0.210
Why?
Necrosis
1
2011
103
0.210
Why?
Bone Neoplasms
3
2006
208
0.200
Why?
Organ Size
1
2011
194
0.200
Why?
Radiotherapy Dosage
6
2000
202
0.200
Why?
Neoplasm Staging
3
2001
354
0.190
Why?
Remission Induction
2
2003
165
0.170
Why?
Sarcoma, Kaposi
2
1998
15
0.170
Why?
Thoracic Neoplasms
1
2009
20
0.170
Why?
Feasibility Studies
2
2006
212
0.170
Why?
Rectal Neoplasms
1
2010
84
0.170
Why?
Adrenal Gland Neoplasms
1
2009
36
0.170
Why?
Gene Expression Regulation, Neoplastic
1
2011
266
0.170
Why?
Neoplasms
2
1999
743
0.170
Why?
Carcinoma, Squamous Cell
2
2006
238
0.160
Why?
Radiation Injuries
2
2006
131
0.160
Why?
Survival Rate
4
2009
619
0.160
Why?
Cognition Disorders
1
2011
291
0.150
Why?
Glioma
1
2008
105
0.150
Why?
Liver
1
2011
884
0.150
Why?
Adenocarcinoma
2
2006
483
0.140
Why?
Prospective Studies
4
2008
1696
0.130
Why?
Follow-Up Studies
4
2003
1889
0.120
Why?
Tumor Markers, Biological
1
2006
240
0.120
Why?
Survival Analysis
5
1996
589
0.110
Why?
Pilot Projects
3
2008
446
0.110
Why?
Lymphatic Metastasis
4
1997
153
0.110
Why?
Etoposide
2
1997
83
0.110
Why?
Fluorouracil
2
1997
78
0.110
Why?
Bronchial Diseases
1
2001
8
0.100
Why?
Radiodermatitis
1
2001
8
0.100
Why?
Lung Diseases, Obstructive
1
2001
43
0.100
Why?
Constriction, Pathologic
1
2001
77
0.100
Why?
Dermatologic Agents
1
2001
24
0.100
Why?
Sesquiterpenes
1
2001
26
0.100
Why?
Umbilicus
1
2000
4
0.100
Why?
Medical Records
1
2001
140
0.100
Why?
Abdominal Neoplasms
1
2000
17
0.090
Why?
Cholecystectomy
1
2000
20
0.090
Why?
Gallbladder Neoplasms
1
2000
8
0.090
Why?
Fatty Acids
1
2001
98
0.090
Why?
Palliative Care
2
1999
161
0.090
Why?
Lipids
1
2001
166
0.090
Why?
Nucleic Acid Synthesis Inhibitors
1
2000
11
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2001
93
0.090
Why?
Antimetabolites, Antineoplastic
1
1999
40
0.090
Why?
Prognosis
3
1997
1078
0.090
Why?
Carcinoma
1
2000
194
0.080
Why?
Double-Blind Method
2
2010
996
0.080
Why?
Melanoma
1
1999
132
0.080
Why?
Laparoscopy
1
2000
213
0.080
Why?
Dose-Response Relationship, Radiation
2
2006
216
0.080
Why?
Treatment Failure
2
2006
131
0.070
Why?
Multivariate Analysis
3
1997
548
0.070
Why?
Israel
3
1996
31
0.060
Why?
Cisplatin
3
1997
93
0.060
Why?
Analysis of Variance
2
1997
749
0.060
Why?
Tomography, X-Ray Computed
2
2006
785
0.060
Why?
Sarcoma
1
2011
64
0.050
Why?
Head and Neck Neoplasms
1
2011
84
0.050
Why?
Interleukin-8
1
2011
111
0.050
Why?
Medical Illustration
1
2010
10
0.050
Why?
Radiation Oncology
1
2010
18
0.050
Why?
Radiotherapy, Conformal
1
2010
19
0.050
Why?
Chemokine CCL2
1
2011
128
0.050
Why?
Colorectal Neoplasms
1
2011
143
0.050
Why?
Esophageal Neoplasms
1
2011
133
0.050
Why?
Observer Variation
1
2010
146
0.050
Why?
Gastrointestinal Tract
1
2009
26
0.040
Why?
Time Factors
2
1999
3234
0.040
Why?
Interleukin-6
1
2011
339
0.040
Why?
Cohort Studies
1
2012
984
0.040
Why?
Jews
2
1996
9
0.040
Why?
Combined Modality Therapy
2
1997
491
0.040
Why?
Kaplan-Meier Estimate
1
2008
207
0.040
Why?
Comorbidity
1
2009
377
0.040
Why?
Young Adult
1
2012
1084
0.040
Why?
Disease Progression
1
2009
533
0.040
Why?
Radiotherapy, Computer-Assisted
1
2006
15
0.040
Why?
Antineoplastic Protocols
1
2006
3
0.040
Why?
Kidney
1
2009
589
0.030
Why?
Emulsions
1
2001
10
0.030
Why?
Skin Pigmentation
1
2001
13
0.020
Why?
Mastectomy, Segmental
1
2001
25
0.020
Why?
Administration, Topical
1
2001
91
0.020
Why?
Antineoplastic Agents, Hormonal
1
2001
44
0.020
Why?
Tamoxifen
1
2001
84
0.020
Why?
Iridium Radioisotopes
1
2000
14
0.020
Why?
Fiber Optic Technology
1
2000
25
0.020
Why?
Postoperative Period
1
2000
89
0.020
Why?
Bronchoscopy
1
2000
30
0.020
Why?
Mitomycin
1
1999
18
0.020
Why?
Bleomycin
1
1999
47
0.020
Why?
Carboplatin
1
1999
29
0.020
Why?
Ethnic Groups
1
2001
160
0.020
Why?
Infusions, Intravenous
1
1999
143
0.020
Why?
Administration, Oral
1
2000
314
0.020
Why?
Arabs
1
1998
2
0.020
Why?
Radiotherapy, Adjuvant
1
1999
74
0.020
Why?
Incidence
1
2001
682
0.020
Why?
Immunocompromised Host
1
1998
85
0.020
Why?
Radiotherapy, High-Energy
1
1997
24
0.020
Why?
Vincristine
1
1997
61
0.020
Why?
Neoplasms, Multiple Primary
1
1997
43
0.020
Why?
Methotrexate
1
1997
73
0.020
Why?
Doxorubicin
1
1997
105
0.020
Why?
Cyclophosphamide
1
1997
177
0.020
Why?
Sunlight
1
1996
15
0.020
Why?
Sex Distribution
1
1996
161
0.020
Why?
Practice Guidelines as Topic
1
1999
319
0.020
Why?
Dose-Response Relationship, Drug
1
1999
1142
0.020
Why?
Age Distribution
1
1996
227
0.020
Why?
Registries
1
1996
218
0.020
Why?
Adolescent
1
1999
5044
0.010
Why?

Visualizations


Katz's Networks

Concepts
_
Co-Authors
_
Same Department